<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christa S Zerbe, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beatriz E Marciano, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven M Holland, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic granulomatous disease (CGD) is a genetically heterogeneous condition characterized by recurrent, life-threatening bacterial and fungal infections and granuloma formation. CGD is caused by defects in the phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex, which constitutes the phagocyte oxidase (phox). These genetic defects result in the inability of phagocytes (neutrophils, monocytes, and macrophages) to destroy certain microbes. The diagnosis is made by neutrophil function testing for superoxide production (nitroblue tetrazolium reduction or dihydrorhodamine [DHR] 123 flow cytometry assay). The exact molecular defect is determined by genotyping.</p><p>Infections in patients with CGD are generally caused by catalase-positive microorganisms (most bacterial and all fungal pathogens are catalase positive), but catalase is neither necessary nor sufficient for pathogenicity in CGD. The frequent sites of infection are the lung, skin, lymph nodes, and liver. Inflammatory complications such as the formation of granulomata are especially problematic in the lungs and the gastrointestinal and genitourinary tracts. Colitis associated with CGD occurs in 30 to 40 percent of all patients with CGD regardless of residual superoxide production and genotype [<a href="#rid1">1</a>].</p><p>This topic reviews the pathogenesis, clinical manifestations, and diagnosis of CGD. The treatment and prognosis of CGD, as well as an overview of primary disorders of phagocyte function, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3923.html" rel="external">"Chronic granulomatous disease: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/3913.html" rel="external">"Primary disorders of phagocyte number and/or function: An overview"</a>.)</p><p class="headingAnchor" id="H1819697907"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The frequency of CGD in the United States is approximately 1:200,000 live births [<a href="#rid2">2</a>]. The disease primarily affects males since over 50 percent of the pathogenic variants are X linked. Rates are almost identical across ethnic and racial groups, with approximately one-third of the X-linked pathogenic variants occurring de novo. However, in cultures in which consanguineous marriage is common, the autosomal recessive forms of CGD are more common than X-linked forms, and overall incidence rates may be higher [<a href="#rid3">3</a>].</p><p>CGD may present at any time from infancy to late adulthood, but the majority of patients are diagnosed as toddlers and children before the age of five years. In several series, the median age at diagnosis was 2.5 to 3 years of age [<a href="#rid4">4-8</a>]. A growing number of patients are diagnosed in later childhood or adulthood due in part to recognition of milder cases of autosomal recessive CGD, as well as delayed diagnosis in some patients. Diagnosis may also be delayed because of newer, potent antimicrobials that inadvertently treat many CGD-associated infections, postponing diagnosis until more severe infections indicate CGD as the underlying cause. X-linked CGD tends to have an earlier onset and be more severe than the most common autosomal recessive form, p47phox deficiency [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Phagocytes use nicotinamide adenine dinucleotide phosphate (NADPH) oxidase to generate reactive species of oxygen. CGD arises from pathogenic variants that result in the loss or functional inactivation of one of the six proteins required to make the NADPH oxidase complex. All of these proteins are necessary for the proper generation of superoxide. (See <a class="local">'Genetic defects'</a> below.)</p><p>The fully assembled NADPH oxidase is a five-protein complex. In the basal state, it exists as two components [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The membrane-bound heterodimer, called cytochrome b-245 or cytochrome b588, that is composed of gp91phox and p22phox and is embedded in the walls of secondary granules</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proteins in the cytosol (p47phox, p67phox, and p40phox)</p><p></p><p>The assembly of the cytochrome is dependent upon a sixth protein that stabilizes the other five in the membrane of the endoplasmic reticulum. This protein is called essential for reactive oxygen species (EROS), encoded by cytochrome b-245 chaperone 1 (<em>CYBC1</em>). The absence of this protein can also cause CGD [<a href="#rid10">10</a>].</p><p>Activation and assembly of the functional oxidase also requires the participation of Rac2, a small guanosine triphosphate (GTP)-binding protein, and Rap1, a small GTPase.</p><p class="headingAnchor" id="H1819698074"><span class="h2">Neutrophil priming</span><span class="headingEndMark"> — </span>Neutrophils exist in one of three states: quiescent, activated, or primed. Primed neutrophils are poised to undergo an exaggerated respiratory burst or secretory response when specific receptors are triggered. (See <a class="local">'Respiratory burst'</a> below.)</p><p>Three main types of agonists are capable of priming neutrophils:</p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory mediators that are chemotactic</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum immunoglobulin and complement</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory cytokines and growth factors such as tumor necrosis factor (TNF) alpha, lipopolysaccharide (LPS), peptidoglycan, granulocyte monocyte colony-stimulating factor (GM-CSF), granulocyte colony stimulation factor (G-CSF), substance P, orthovanadate, and interleukin (IL) 1</p><p></p><p>Priming may be achieved rapidly, over a few minutes, or more slowly, over 30 minutes, depending upon the nature of the stimulus. The primed state is transient, lasting up to several hours.</p><p class="headingAnchor" id="H3"><span class="h2">Activation of NADPH oxidase</span><span class="headingEndMark"> — </span>The cytosolic components p47phox and p67phox are phosphorylated and bind tightly together after cellular activation is initiated by phagocytosis of microbes. In association with p40phox and Rac2, these proteins combine with the membrane-bound cytochrome complex (gp91phox and p22phox) to form the intact nicotinamide adenine dinucleotide phosphate (NADPH) oxidase  (<a class="graphic graphic_figure graphicRef72548" href="/z/d/graphic/72548.html" rel="external">figure 1</a>) [<a href="#rid9">9</a>].</p><p>The source of reducing equivalents for the respiratory burst oxidase and the glutathione detoxification pathway is NADPH [<a href="#rid11">11-14</a>]. This compound is replenished from NADP by glucose-6-phosphate dehydrogenase (G6PD) through the hexose monophosphate shunt.</p><p class="headingAnchor" id="H4"><span class="h2">Respiratory burst</span><span class="headingEndMark"> — </span>After the NADPH oxidase has formed, an electron is then taken from NADPH and donated to molecular oxygen, leading to the formation of superoxide. This is converted to hydrogen peroxide spontaneously or enzymatically by superoxide dismutase. In the final step, hydrogen peroxide reacts with superoxide anion, forming a highly reactive hydroxyl radical that is converted to hypochlorous acid in the presence of myeloperoxidase and chlorine in the neutrophil phagosome  (<a class="graphic graphic_figure graphicRef72548" href="/z/d/graphic/72548.html" rel="external">figure 1</a>). The rapid consumption of oxygen and production of superoxide and its metabolites is referred to as the "respiratory burst." Phagocyte production of reactive oxygen species (ROS) leads to potassium and proton influx into the phagolysosome, leading to activation of granule proteases, including elastase and cathepsin G. These proteases are responsible for the destruction of ingested (phagocytosed) microorganisms. Thus, superoxide acts as an intracellular-activating molecule in addition to a direct microbicidal molecule as previously thought [<a href="#rid15">15-18</a>]. This model also explains why patients with myeloperoxidase deficiency (MPO) do not develop the same infections as patients with CGD.</p><p class="headingAnchor" id="H6"><span class="h2">Innate immune receptors</span><span class="headingEndMark"> — </span>Foreign material, such as bacteria, fungi, and parasites, display molecules that are not seen in higher organisms. Termed pathogen-associated molecular patterns (PAMPs), these molecular components of microorganisms are recognized by receptors globally referred to as pattern recognition receptors that include Toll-like receptors (TLRs). Patients with CGD, compared with the general population of patients with bacterial pneumonia, express lower levels of several neutrophil receptors, including TLRs (TLR5 and TLR9), complement receptors (CD11b, CD18, and CD35), and a chemokine receptor (CXCR1). In contrast, patients with pneumonia who do not have CGD generally have higher than normal expression levels of these proteins. Decreased expression results in impaired neutrophil activation (TLR5), phagocytosis (CD11b/CD18), and chemotaxis (CXCR1). Levels of expression of TLR5 and CD18 may correlate with CGD disease severity [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H11501362"><span class="h2">Neutrophil extracellular traps</span><span class="headingEndMark"> — </span>Neutrophils can continue to participate in antimicrobial activity even after they undergo apoptosis. During neutrophil cell death, the nuclei swell, chromatin dissolves, and large strands of decondensed deoxyribonucleic acid (DNA) extrude from the cell, carrying with them proteins from cytosol, granules, and histones from the nuclei themselves [<a href="#rid20">20,21</a>]. These neutrophil extracellular traps (NETs) entangle and may contribute to the extracellular killing of bacteria and fungi [<a href="#rid21">21,22</a>]. NET formation is probably enhanced by hydrogen peroxide, and therefore patients with CGD do not form normal NETs [<a href="#rid22">22-24</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Enhanced inflammation</span><span class="headingEndMark"> — </span>Several different mechanisms may be involved in the enhanced inflammation seen in patients with CGD.</p><p class="headingAnchor" id="H9"><span class="h3">Inflammatory mediators</span><span class="headingEndMark"> — </span>Defective production of ROS leads to increased expression of nuclear factor (NF) kappa-B-regulated inflammatory genes [<a href="#rid25">25</a>]. Higher levels of inflammatory mediators are expressed in monocytes from patients with X-linked CGD without acute infection compared with controls. A similar increase in transcription of antiinflammatory mediators is not seen.</p><p class="headingAnchor" id="H332136455"><span class="h3">Inflammasome activation</span><span class="headingEndMark"> — </span>ROS dampen inflammasome activation in healthy individuals. This inhibition is impaired in patients with CGD [<a href="#rid26">26-28</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Efferocytosis</span><span class="headingEndMark"> — </span>Efferocytosis is the process by which apoptotic inflammatory cells are recognized and removed by phagocytes. Impaired efferocytosis has been demonstrated in macrophages in a mouse model of CGD [<a href="#rid29">29</a>] and in monocyte-derived macrophages from patients with CGD [<a href="#rid30">30</a>]. Defects in efferocytosis are suspected to contribute to the granulomatous inflammation seen in CGD. Treatment with <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> restores efferocytosis, but it remains to be seen whether this therapy can alter the immune and inflammatory defects seen in CGD in vivo [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H1819697598"><span class="h1">GENETIC DEFECTS</span><span class="headingEndMark"> — </span>Pathogenic variants in the genes for the six proteins (gp91phox, p47phox, p22phox, p67phox, p40phox, and essential for reactive oxygen species [EROS]) that are required to make the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex account for all of the known cases of CGD. There are one X-linked and five autosomal recessive forms of CGD [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The gene for <strong>gp91phox</strong> is encoded by cytochrome b-245, beta subunit (<em>CYBB</em>), located at chromosome Xp21.1. Defects in this gene cause X-linked CGD (MIM #306400), which accounts for approximately 65 to 70 percent of cases in the United States and Europe [<a href="#rid32">32</a>]. Missense or splicing mutations may be associated with some low levels of residual superoxide production. Patients with these pathogenic variants generally have better survival than those with nonsense or deletion mutations that leave no residual superoxide production [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second membrane component, <strong>p22phox</strong>, is encoded by<em> </em>cytochrome b-245, alpha subunit (<em>CYBA</em>), located at chromosome 16q24. Defects in this gene cause an autosomal recessive CGD (MIM #233690), which accounts for less than 5 percent of cases [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cytosolic factor <strong>p47phox</strong> is encoded by neutrophil cytosolic factor 1 (<em>NCF1</em>), located at chromosome 7q11.23 (MIM #233700). Defects in this gene account for approximately 25 percent of North American cases. Approximately 80 percent of p47phox deficiency is due to a GT (guanine-thymine) deletion in exon 2 that is associated with residual superoxide production [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cytosolic factor, <strong>p67phox</strong>, is encoded by neutrophil cytosolic factor 2 (<em>NCF2</em>), located at chromosome 1q25 (MIM #233710). Defects in <em>NCF2</em> account for less than 5 percent of cases [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cytosolic factor, <strong>p40phox</strong>, is encoded by neutrophil cytosolic factor 4 (<em>NCF4</em>), located at chromosome 22a13.1 (MIM #601488). Recessive defects in <em>NCF4</em> cause a mildly impaired respiratory burst activity (may appear normal on standard neutrophil dihydrorhodamine 123 [DHR] testing) but severe inflammatory bowel disease (IBD) [<a href="#rid36">36,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The assembly of the cytochrome complex occurs in the endoplasmic reticulum and is dependent upon EROS (encoded by cytochrome b-245 chaperone 1 [<em>CYBC1</em>]), located at chromosome 17q25.3. A handful of patients with CGD due to autosomal recessive pathogenic variants in <em>CYBC1</em> (MIM #618334) have been identified [<a href="#rid10">10,38</a>].</p><p></p><p>Neutrophil immunodeficiency syndrome, a syndrome with some overlap with CGD in terms of superoxide production but also with distinct neutrophil chemotaxis defects and T cell dysfunction [<a href="#rid39">39</a>], is caused by a dominant-negative pathogenic variant in the Ras-related C3 botulinum toxin substrate 2 (<em>RAC2</em>) gene. Patients with dominant-negative variants in <em>RAC2</em> may have impaired superoxide production, impaired chemotaxis and adhesion, low T cell receptor excision circles (TRECs), severe bacterial infections, and poor wound healing [<a href="#rid40">40,41</a>]. In contrast, dominant activating <em>RAC2</em> variants cause excessive superoxide production with impaired neutrophil migration and severe T and B cell lymphopenia [<a href="#rid42">42</a>].</p><p>The large majority of the identified pathogenic variants in the phagocyte oxidase (phox) proteins result in complete or nearly complete absence of the protein. A normal amount of a nonfunctioning or hypofunctioning protein results from the other (minority) variants. The superscripts <sup>+</sup>, <sup>-</sup>, and <sup>0</sup> have been used to indicate normal, decreased, or absent protein levels, respectively [<a href="#rid9">9</a>].</p><p>A macrophage-specific defect in gp91phox expression appears to predispose more to localized Bacillus Calmette-Guérin (BCG) infection and tuberculosis (TB) than the other infections typically seen in CGD [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with CGD usually present with recurrent or severe infections caused by bacteria or fungi. Other presenting features include growth failure, abnormal wound healing, diarrhea, and granulomatous dermatitis. Patients with CGD may have hepatomegaly, splenomegaly, or lymphadenitis [<a href="#rid44">44</a>] on physical examination.</p><p class="headingAnchor" id="H14"><span class="h2">Infections</span><span class="headingEndMark"> — </span>Patients with CGD typically experience repeated infections caused by bacterial and fungal pathogens. However, CGD patients may exhibit few clinical signs and symptoms, despite the presence of significant infection. Response to viral infections is normal in patients with CGD. Lower residual superoxide production is associated with a higher risk of severe infections and a higher mortality, but it does not affect the rates of CGD-related colitis [<a href="#rid45">45</a>].</p><p>Bacterial infections in CGD tend to be symptomatic and are typically associated with fever, pleuritic chest pain, and inflammatory marker (eg, C-reactive protein [CRP]) elevation but only mildly elevated leukocyte counts [<a href="#rid46">46</a>]. In contrast, fungal infections are typically associated with little to no fever and lower leukocytosis and are therefore more difficult to recognize clinically. Fungal infections are often detected either at asymptomatic stages on routine screening for infections [<a href="#rid47">47</a>] or at an advanced stage. As an example, patients with fungal osteomyelitis may not be diagnosed until later stages of disease, when they have multiorgan involvement [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Sites of infection</span><span class="headingEndMark"> — </span>The most common sites of infection are the lung, skin, lymph nodes, and liver [<a href="#rid2">2</a>].</p><p>The types of serious infections most often seen (in descending order of frequency) include [<a href="#rid45">45,49</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumonia</p><p class="bulletIndent1"><span class="glyph">●</span>Abscesses (skin, tissue, organs)</p><p class="bulletIndent1"><span class="glyph">●</span>Suppurative adenitis</p><p class="bulletIndent1"><span class="glyph">●</span>Osteomyelitis</p><p class="bulletIndent1"><span class="glyph">●</span>Bacteremia/fungemia</p><p class="bulletIndent1"><span class="glyph">●</span>Superficial skin infections (cellulitis/impetigo)</p><p></p><p>Pneumonia is the most common pulmonary infection, but patients may also have lung abscesses, empyema, and hilar lymphadenopathy. In contrast to what occurs in neutropenic patients, fungal pneumonias do not generally cavitate in CGD, whereas <em>Nocardia</em> infections do. In a series of adults with CGD, over one-third with invasive pulmonary fungal infections were asymptomatic [<a href="#rid50">50</a>].</p><p>The most common sites for abscesses are perianal/perirectal and the liver. Gingivitis, stomatitis, gastroenteritis, and otitis are also common [<a href="#rid2">2,4-7,9</a>].</p><p class="headingAnchor" id="H16"><span class="h3">Organisms</span><span class="headingEndMark"> — </span>In general, the organisms that infect patients with CGD are catalase producing. Catalase is an enzyme that inactivates the hydrogen peroxide normally produced by some bacteria and fungi during growth. Although most microorganisms produce hydrogen peroxide, some do not. It was thought that CGD phagocytes could use the hydrogen peroxide produced by catalase-negative microbes to generate reactive oxidants, thereby bypassing the intrinsic CGD defect. However, the majority of pathogens in general are catalase positive, and only a few cause infections in CGD, suggesting that catalase production alone is insufficient for pathogenicity. Furthermore, targeted deletion of the catalase genes in <em>Aspergillus nidulans</em> and <em>Staphylococcus aureus</em> did not affect virulence in animal models of CGD, indicating that microbial catalase is not a significant virulence factor for CGD infections.</p><p>The overwhelming majority of severe infections in North America are due to five organisms (estimated incidence of severe infections in 268 patients followed at a single center over a 40-year period is shown) [<a href="#rid45">45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><em>Aspergillus</em> species (2.6 cases per 100 patient-years)</p><p class="bulletIndent1"><span class="glyph">●</span><em>S. aureus</em> (1.44 per 100 patient-years)</p><p class="bulletIndent1"><span class="glyph">●</span><em>Burkholderia</em> (<em>Pseudomonas</em>) <em>cepacia</em> complex (1.06 per 100 patient-years)</p><p class="bulletIndent1"><span class="glyph">●</span><em>Serratia marcescens</em> (0.98 per 100 patient-years)</p><p class="bulletIndent1"><span class="glyph">●</span><em>Nocardia</em> species (0.81 per 100 patient-years)</p><p></p><p>Another series of 27 patients followed at a different center in North America from 1985 to 2013 found that the most common causes of severe infections, in order of frequency, were <em>S. aureus</em>, <em>Serratia</em>, <em>Klebsiella</em>, <em>Aspergillus</em>, and <em>Burkholderia </em>[<a href="#rid49">49</a>].</p><p>Outside of North America, <em>Salmonella</em> and Bacillus Calmette-Guérin (BCG) are frequent infections and should suggest the diagnosis. Other organisms isolated less frequently include <em>Streptococcus</em> species, <em>Neisseria meningitidis</em>, <em>Acinetobacter junii</em>, <em>Candida</em> species, <em>Klebsiella pneumoniae</em> and <em>Klebsiella</em> <em>oxytoca</em>, <em>Mycobacterium tuberculosis</em>, nontuberculous mycobacteria, <em>Proteus</em> species, <em>Actinomyces</em> [<a href="#rid51">51</a>]<em>, </em>methylotrophic bacteria [<a href="#rid52">52</a>], and <em>Leishmania</em> species [<a href="#rid4">4,6,7</a>].</p><p class="headingAnchor" id="H17"><span class="h3">Bacterial infections</span><span class="headingEndMark"> — </span>The frequency of bacterial infections in CGD has decreased since <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> prophylaxis became routine in the 1980s. Most lung, skin, and bone infections were staphylococcal in the preprophylaxis era. On prophylaxis, staphylococcal infections are essentially confined to the liver, lymph nodes, and skin [<a href="#rid2">2</a>]. Severe, resistant facial acne and painful inflammation of the nares are common infectious skin manifestations of <em>S. aureus</em> infection. Other bacteria and fungi are now the more common causes of lung and bone infections in patients with CGD. (See  <a class="medical medical_review" href="/z/d/html/3923.html" rel="external">"Chronic granulomatous disease: Treatment and prognosis", section on 'Antibacterial prophylaxis'</a>.)</p><p><em>B. cepacia</em> complex, which is a common cause of pneumonia with primarily endobronchial disease in patients with cystic fibrosis (CF), can cause pneumonia with nodular infiltrates in patients with CGD, as well as hemophagocytic lymphohistiocytosis (HLH) [<a href="#rid53">53-56</a>]. Patients with CGD are prone to recurrent pulmonary infection with different strains of <em>Burkholderia</em>, unlike patients with CF, who tend to have chronic infection with the same strain [<a href="#rid54">54</a>].</p><p>Infants often present with <em>Serratia marcescens</em> bone and soft tissue infections [<a href="#rid48">48</a>]. <em>S. marcescens</em> infections still occur in older children and adults with CGD, but the pattern of presentation is different [<a href="#rid57">57</a>]. Osteomyelitis is rare, but disseminated abscesses and skin infections with large, poorly healing ulcers are common.</p><p>Mycobacterial infections accounted for almost 6 percent of pneumonias in American CGD surveys in 2000 and 2007 [<a href="#rid2">2,58</a>]. A high incidence of tuberculosis (TB) was observed in CGD patients living in areas endemic for TB [<a href="#rid59">59,60</a>]. Draining skin lesions at sites of BCG vaccination are seen in CGD patients, although these infections do not usually disseminate, as occurs in infants with severe combined immunodeficiency (SCID). However, dissemination of BCG may be strain dependent since numerous cases of disseminated BCG in CGD have been reported in particular countries where different strains are found [<a href="#rid61">61</a>].</p><p><em>Granulibacter bethesdensis</em> is an environmental organism that can cause fever, weight loss, and necrotizing pyogranulomatous lymphadenitis [<a href="#rid62">62,63</a>]. Fatal bacteremia and meningitis have been also reported [<a href="#rid64">64,65</a>].</p><p>Bacteremia is uncommon, but, when it occurs, it is usually due to the following organisms:</p><p class="bulletIndent1"><span class="glyph">●</span><em>B. cepacia</em> complex [<a href="#rid66">66-68</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>S. marcescens</em>, which is also a common cause of bacterial osteomyelitis [<a href="#rid48">48</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Chromobacterium violaceum</em>, a gram-negative rod found in brackish water, especially in the Southeastern United States [<a href="#rid69">69,70</a>]</p><p></p><p>Infection with catalase-negative organisms is uncommon, but severe chronic recurrent actinomycosis has been reported [<a href="#rid51">51</a>]. All patients in one series presented with a prolonged history of fever and clinical signs of infection without an obvious focus. Sites of infection were cervicofacial, hepatic, and/or pulmonary [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H18"><span class="h3">Fungal infections</span><span class="headingEndMark"> — </span>Fungal infections remain the leading causes of mortality in CGD [<a href="#rid2">2</a>], even though the rate of fungal infections is lower than bacterial infections. The frequency of, and mortality from, fungal infections has been markedly reduced since the advent of <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> prophylaxis and the use of <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> and <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> for treatment of filamentous fungal infections (eg, <em>Aspergillus</em>). However, fungal infections continue to occur, even in those on azole antifungal prophylaxis [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/3923.html" rel="external">"Chronic granulomatous disease: Treatment and prognosis", section on 'Antifungal prophylaxis'</a>.)</p><p>The fungal organisms that break through azole prophylaxis are usually resistant and require more aggressive diagnosis and therapy. A major recognition has been that the organisms frequently determined morphologically to be <em>Aspergillus fumigatus</em> are, in fact, non-<em>fumigatus</em> <em>Aspergillus</em> species, which is best determined by molecular speciation. Many of these organisms are more virulent in CGD than <em>A. fumigatus</em>, require combination antifungal therapy, and may require surgical management [<a href="#rid72">72,73</a>]. Similarly, morphologic diagnosis can be misleading for organisms often thought to be <em>Paecilomyces variotii</em> that are in fact the more treatment-refractory <em>Geosmithia argillacea</em> [<a href="#rid74">74,75</a>].</p><p>Fungal infections typically begin in the lung after inhalation of spores or hyphae. Fungal spores are common in the air in general, but specific exposures are problematic for patients with CGD, such as gardening, yard work, lawn mowing, leaf raking, and mulching. Fungal pneumonia may spread locally to ribs and spine or metastatically to brain. <em>Aspergillus nidulans</em>, an organism that infects patients with CGD almost exclusively, causes a significantly higher rate of osteomyelitis and mortality than other fungi [<a href="#rid47">47,76</a>]. <em>Penicillium piceum</em> is a relatively nonpathogenic fungus that can produce lung nodules and osteomyelitis in CGD [<a href="#rid77">77</a>]. In contrast, zygomycosis is rare in patients with CGD and is typically associated with iatrogenic immune suppression [<a href="#rid78">78</a>]. Histoplasmosis and coccidioidomycosis have not been reported in patients with CGD.</p><p class="headingAnchor" id="H19"><span class="h2">Inflammatory and other manifestations</span><span class="headingEndMark"> — </span>Patients with CGD are also prone to granulomata of various organs, growth retardation, chronic pulmonary disease, and autoimmune disorders including inflammatory bowel disease (IBD). In contrast to many other immunodeficiencies, CGD is probably not associated with an increased incidence of neoplasia, although several cancers have been identified in patients with CGD [<a href="#rid79">79</a>]. The microbiome is an essential regulator of inborn errors of immunity, with accumulating evidence of connections between altered gut microbiota and clinical symptoms [<a href="#rid80">80-82</a>]. The microbiome is abnormal in CGD-associated colitis, and altered functional characteristics probably contribute to pathogenesis [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H20"><span class="h3">Granulomata</span><span class="headingEndMark"> — </span>Patients with CGD are prone to the formation of granulomata. These can affect any hollow viscus but are especially problematic in the gastrointestinal and genitourinary tracts [<a href="#rid84">84</a>]. Other tissues and organs, such as the retina, liver, lungs, and bone, may also be affected by granulomata [<a href="#rid85">85</a>]. The reasons for granuloma formation in CGD are unknown, but CGD cells fail to degrade chemotactic and inflammatory signals normally and fail to degrade apoptotic cells normally, which may lead to persistent and exuberant inflammation.</p><p class="headingAnchor" id="H21"><span class="h3">Gastrointestinal</span><span class="headingEndMark"> — </span>Gastrointestinal manifestations of CGD include abdominal pain, diarrhea, colitis, proctitis, strictures, fistulae, and obstruction. In a series of 140 CGD patients, 43 percent of X-linked and 11 percent of autosomal recessive CGD patients had gastrointestinal manifestations [<a href="#rid1">1</a>]. All patients with confirmed IBD complained of abdominal pain. Diarrhea was reported in 39 percent and nausea and vomiting in 24 percent. Thirty-five percent had gastrointestinal obstruction (gastric, esophageal, duodenal, and other). Bowel strictures and fistulae are present in a significant number of patients. Upper gastrointestinal tract inflammatory disease is common, although typically not as severe as colonic disease [<a href="#rid86">86</a>].</p><p>Sixty-five percent of the patients in one series with gastrointestinal involvement had either granulomatous or ulcerative colonic lesions [<a href="#rid1">1</a>]. Crohn disease and ulcerative colitis were diagnosed in only 20 percent of those with inflammatory bowel lesions. The CGD genotype appears to accentuate the standard genetic risks associated with IBD [<a href="#rid87">87</a>]. CGD should be on the differential in early-onset IBD [<a href="#rid88">88</a>]. The granulomata in CGD IBD were characterized by sharply defined histiocyte aggregates with surrounding lymphocytic inflammation, unlike the poorly formed granulomata seen in Crohn disease. However, when staining for the macrophage marker CD68 was done, CGD bowel disease had much lower levels of staining than either normal patients or patients with Crohn disease who did not have CGD [<a href="#rid89">89</a>]. This appears to be related to CD68 expression since other markers of macrophage number are similar between Crohn disease and CGD. While IBD is common in CGD, the rate of CGD in general IBD is not clear; it may account for approximately 1 percent of cases. Genome-wide association studies (GWAS) in patients with early-onset IBD have repeatedly identified the genes involved in the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase [<a href="#rid90">90</a>].</p><p>It is important to keep CGD granulomatous colitis in mind since patients with CGD have a much worse (and sometimes fatal) outcome with tumor necrosis factor (TNF) alpha inhibition (eg, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>) than do typical patients with Crohn disease [<a href="#rid91">91,92</a>]. (See  <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children"</a> and  <a class="medical medical_review" href="/z/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors"</a> and  <a class="medical medical_review" href="/z/d/html/3923.html" rel="external">"Chronic granulomatous disease: Treatment and prognosis", section on 'Therapy for inflammatory manifestations'</a>.)</p><p class="headingAnchor" id="H22"><span class="h4">Hepatic</span><span class="headingEndMark"> — </span>Liver abnormalities are frequently identified. In a CGD cohort of 194 patients, liver enzymes were elevated in 73 percent, with persistent elevations of alkaline phosphatase seen in 25 percent. Drug-induced hepatitis was reported in 15 percent. In patients with abnormal liver enzymes who underwent liver biopsy, histology revealed granulomata in 75 percent and lobular hepatitis in 90 percent. Eighty percent of patients had a portal venopathy that was often associated with splenomegaly. Liver abscesses and hepatomegaly were each seen in one-third of cases. Portal hypertension was an important risk factor for mortality and was strongly suggested by a decreasing platelet count over time [<a href="#rid93">93,94</a>].</p><p class="headingAnchor" id="H23"><span class="h3">Genitourinary</span><span class="headingEndMark"> — </span>Urologic disorders are fairly common. In a series of 60 CGD patients, approximately 40 percent of patients had urologic manifestations, including ureteral and urethral strictures, urinary tract infections, altered kidney function, and bladder granulomata [<a href="#rid95">95</a>]. Colitis associated with CGD can also result in fistula formation causing urogenital tract dysfunction [<a href="#rid96">96</a>]. All patients with urologic strictures had defects of the membrane component of the NADPH oxidase (gp91phox or p22phox).</p><p class="headingAnchor" id="H24"><span class="h3">Ophthalmic</span><span class="headingEndMark"> — </span>Chorioretinal lesions are described in up to one-quarter of patients with X-linked CGD [<a href="#rid97">97</a>] and are also detected in some X-linked female carriers. These lesions are mostly asymptomatic retinal scars associated with pigment clumping. Some of these lesions contain bacterial DNA (detected by polymerase chain reaction [PCR]) [<a href="#rid98">98</a>]. The clinical meaning of this finding is unclear, but it may reflect remote seeding. However, these lesions do not progress despite aggressive immunosuppression in some cases, suggesting that they are not sites of active infection. Keratitis has also been reported [<a href="#rid4">4</a>]. (See <a class="local">'X-linked carriers'</a> below.)</p><p class="headingAnchor" id="H25"><span class="h3">Pulmonary</span><span class="headingEndMark"> — </span>Chronic respiratory disease, presumably due to recurrent pulmonary infections, is common, particularly in adults [<a href="#rid4">4,50,84</a>]. Findings on chest computed tomography (CT) include bronchiectasis, obliterative bronchiolitis, and chronic fibrosis [<a href="#rid4">4,84</a>]. (See  <a class="medical medical_review" href="/z/d/html/15830.html" rel="external">"Pulmonary complications of primary immunodeficiencies", section on 'Chronic granulomatous disease'</a>.)</p><p>A clinical entity specific to CGD is mulch pneumonitis, so-called because patients with CGD can develop a characteristic syndrome of dyspnea, hypoxia, and fever leading to respiratory failure and death within 1 to 10 days after inhalation of large burdens of fungal spores and hyphae, such as those found in mulch, hay, peat moss, or dirt [<a href="#rid99">99</a>]. This syndrome is important to recognize since it is best treated with simultaneous administration of glucocorticoids and antifungals.</p><p>Potentially noninfectious respiratory events (defined as a radiologic pulmonary opacity that often has an inflammatory pattern and is not proven to be caused by an infection) are common in adults with CGD, occurring in 28 percent of adults in one series [<a href="#rid50">50</a>]. Approximately two-thirds of these patients presented with respiratory symptoms, and most received treatment with immunomodulatory therapies, such as systemic glucocorticoids with or after treatment for infections.</p><p class="headingAnchor" id="H26"><span class="h3">Oral</span><span class="headingEndMark"> — </span>Recurrent aphthous ulceration is common in CGD and especially common in X-linked carriers. Other oral manifestations may include periodontitis, gingivitis, and gingival hypertrophy [<a href="#rid4">4,100,101</a>].</p><p class="headingAnchor" id="H27"><span class="h3">Skin</span><span class="headingEndMark"> — </span>Noninfectious skin manifestations of CGD include photosensitivity, discoid lupus, granulomatous lesions, and vasculitis [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H28"><span class="h3">Autoimmune</span><span class="headingEndMark"> — </span>Autoimmune disorders are more common in CGD, affecting up to 5 percent of patients [<a href="#rid2">2</a>]. Both discoid and systemic lupus erythematosus (SLE) have been described and occur with at least the same frequency in X-linked CGD female carriers as in patients [<a href="#rid102">102,103</a>]. Immune thrombocytopenia (ITP) and juvenile idiopathic arthritis (JIA) are also more frequent in CGD than in the general population [<a href="#rid2">2</a>]. Other reported autoimmune diseases in patients with CGD include fibrotic pulmonary disease, immunoglobulin A (IgA) nephropathy, antiphospholipid syndrome, and recurrent pericardial effusion [<a href="#rid104">104</a>].</p><p class="headingAnchor" id="H29"><span class="h3">Growth retardation</span><span class="headingEndMark"> — </span>Patients with CGD commonly experience growth retardation. Failure to thrive is a frequent presenting symptom in young children. In one series of 94 patients, approximately 75 percent were below the population mean for height and weight at the time of diagnosis [<a href="#rid4">4</a>]. Thirty-five percent required nasogastric and/or parenteral nutritional supplementation. In another small series of 23 patients, approximately 20 percent were below the 10<sup>th</sup> percentile for height and weight [<a href="#rid5">5</a>]. Growth often improves in late adolescence [<a href="#rid105">105</a>], and many patients with CGD attain their expected growth potential by adulthood. Hematopoietic cell transplantation appears to correct most cases of growth retardation regardless of the cause [<a href="#rid106">106</a>].</p><p class="headingAnchor" id="H30"><span class="h3">McLeod syndrome</span><span class="headingEndMark"> — </span>The Kell metallo-endopeptidase (<em>KEL</em>) gene locus on chromosome 7q33 encodes the Kell blood group proteins, of which there are more than 25 antigens. The Kell blood group system is formed by two disulfide-linked proteins, Kell and Kx, which is encoded by X-linked Kx blood group (<em>XK</em>), telomeric to <em>CYBB</em> on chromosome Xp21. Patients with deletions in the X chromosome may have deletions in portions of both <em>CYBB</em> and <em>XK</em> (contiguous gene disorder) and thereby present with X-linked CGD and McLeod syndrome. McLeod syndrome causes acanthocytosis and low or absent expression of the erythrocyte blood group Kell antigens, Kell(-). This may result in anemia, elevated creatine phosphokinase, and late-onset peripheral and central nervous system manifestations. (See  <a class="medical medical_review" href="/z/d/html/7088.html" rel="external">"Burr cells, acanthocytes, and target cells: Disorders of red blood cell membrane", section on 'Blood group abnormalities'</a> and  <a class="medical medical_review" href="/z/d/html/14122.html" rel="external">"Neuroacanthocytosis", section on 'Mcleod syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">"Red blood cell antigens and antibodies", section on 'Kell blood group system'</a>.)</p><p>Special care has to be taken when transfusing patients with X-linked CGD/McLeod syndrome to avoid Kell(+) transfusions into these Kell(-) patients [<a href="#rid107">107,108</a>]. All X-linked CGD patients should be tested for Kell antigens. Those who test negative should have this noted on their medical record and wear medical identification jewelry stating that they must be given Kell(-) blood if they require a transfusion.</p><p class="headingAnchor" id="H1819698399"><span class="h2">X-linked carriers</span><span class="headingEndMark"> — </span>The X-linked carrier state for gp91phox is neither silent nor static. In affected females, lyonization (the inactivation of one or the other X chromosome in every cell) leads to two populations of phagocytes: one with normal respiratory burst function (positive dihydrorhodamine [DHR] 123 test) and the other with impaired respiratory burst activity [<a href="#rid109">109</a>]. Therefore, X-linked CGD carriers display a characteristic mosaic pattern on respiratory burst testing of peripheral blood cells as seen microscopically (nitroblue tetrazolium [NBT] test) or by flow cytometry (DHR test). (See <a class="local">'Neutrophil function tests'</a> below.)</p><p>As few as 20 percent of cells having normal respiratory burst activity is sufficient to prevent most severe bacterial and fungal infections. Thus, most female carriers of X-linked gp91phox CGD variants are not compromised in their ability to handle infections. However, carriers with less than 20 percent of normal oxidase activity due to skewed X-chromosome lyonization may present with the phenotype of mild to severe CGD [<a href="#rid110">110-113</a>]. In a large series of X-linked carriers, those with &lt;20 percent DHR+ cells had serious infectious complications, while all carriers, regardless of percent DHR+ cells, had increased rates of inflammatory and autoimmune complications [<a href="#rid114">114</a>]. In addition, progressive skewing of X-chromosome inactivation with age in previously healthy carriers of gp91phox null variants can lead to late-onset manifestations of CGD [<a href="#rid115">115</a>]. Females may have other manifestations of heterozygous carriage of X-linked CGD variants, including discoid lupus erythematosus, aphthous ulcers, chorioretinal lesions, and photosensitivity [<a href="#rid116">116,117</a>], which are not dependent upon the degree of lyonization but appear to correlate with lyonization per se [<a href="#rid118">118</a>].</p><p class="headingAnchor" id="H1913274158"><span class="h1">LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>Certain abnormalities in routine laboratory tests are associated with the disease, although these are not required for diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypergammaglobulinemia, possibly due to chronic inflammation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low numbers of circulating memory B cells [<a href="#rid119">119</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD4 T cell lymphocytopenia, which may be marked, but does not correlate with infection risk nor predispose to T cell-dependent pathogens [<a href="#rid120">120</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anemia of chronic disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), usually in the presence of infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypoalbuminemia, found in 70 percent of patients with gastrointestinal involvement and 25 percent without gastrointestinal manifestations [<a href="#rid1">1</a>]</p><p></p><p class="headingAnchor" id="H31"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Patients suspected of having CGD should initially undergo neutrophil-function testing. Positive findings should be confirmed by genotyping. It is important to appreciate that the p47phox pathogenic variant is due to a pseudogene conversion and so may not be detectable by standard sequencing. In these cases, an immunoblot or gene dose determination may be needed to confirm p47phox deficiency.</p><p>A history of recurrent and/or unusually severe infections, particularly abscesses and infections caused by the pathogens commonly associated with CGD, should prompt functional or genetic screening. Neonatal or early postnatal screening of potentially affected children is essential with a family history of CGD. (See <a class="local">'Infections'</a> above.)</p><p class="headingAnchor" id="H32"><span class="h2">Neutrophil function tests</span><span class="headingEndMark"> — </span>Diagnostic tests for CGD rely on various measures of neutrophil superoxide production. These include direct measurement of superoxide production, cytochrome c reduction assay, chemiluminescence, nitroblue tetrazolium (NBT) reduction test, and dihydrorhodamine (DHR) 123 oxidation test.</p><p>Most prefer the DHR test because of its objectivity, relative ease of use, ability to distinguish between X-linked and autosomal forms of CGD, and the ability to detect gp91phox carriers [<a href="#rid121">121,122</a>]. Other tests can also provide reliable diagnosis of CGD but either cannot distinguish carrier status or require significant operator experience.</p><p class="headingAnchor" id="H33"><span class="h3">Dihydrorhodamine 123 test</span><span class="headingEndMark"> — </span>In this test, the nonfluorescent rhodamine derivative, DHR, is taken up by phagocytes and oxidized to a green fluorescent compound by products of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase  (<a class="graphic graphic_figure graphicRef68461" href="/z/d/graphic/68461.html" rel="external">figure 2</a>). The sensitivity and quantitative nature of this assay make it possible to differentiate oxidase-positive from oxidase-negative phagocyte subpopulations in CGD carriers and identify deficiencies in gp91phox and p47phox. DHR testing can also be quantitated to allow for allocation of cellular response into more and less impaired subgroups. The degree of residual superoxide production as measured by DHR testing provides important prognostic information that dovetails with genetic information [<a href="#rid33">33,123</a>]. (See <a class="local">'Genetic testing'</a> below.)</p><p>Other conditions that affect the neutrophil respiratory burst, giving abnormal DHR test results but normal measures of extracellular superoxide production (eg, cytochrome c reduction or NBT tests), include myeloperoxidase deficiency and the syndrome of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) [<a href="#rid124">124,125</a>]. The DHR test can also be used to determine chimerism status following hematopoietic cell transplantation [<a href="#rid126">126,127</a>]. Several reference laboratories in the United States and around the world offer these assays.</p><p class="headingAnchor" id="H34"><span class="h3">Nitroblue tetrazolium test</span><span class="headingEndMark"> — </span>The oldest laboratory test for CGD is the NBT test. This provides a simple and rapid (but largely qualitative) determination of phagocyte NADPH oxidase activity. Superoxide produced by normal peripheral blood neutrophils stimulated in vitro reduces yellow NBT to dark-blue/black formazan, which forms a precipitate in the cells. Normal phagocyte oxidase activity will result in at least 95 percent positive cells in this assay. X-linked carriers can be identified with this test. Test limitations include a higher rate of false-negative results and operator subjectivity.</p><p class="headingAnchor" id="H36"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>The clinical history usually suggests autosomal recessive or X-linked disease, based on sex, consanguinity, age at presentation, and severity. A diagnosis of CGD based on abnormal neutrophil function should be followed by genetic testing. Sequencing of the patient's phagocyte oxidase (phox) genes to determine the exact molecular defect is recommended. Genetic testing is available through specialized commercial laboratories and selected tertiary referral centers. The most common p47phox defect can be difficult to identify genetically as it is caused by pseudogene conversion and may be missed in typical sequencing studies. For these cases, immunoblotting or flow cytometry can show absence of protein. An amplification of the various pseudogenes can also be performed to prove loss of the functional allele.</p><p>Genetic testing is increasingly important in the risk profiling of CGD. Pathogenic variants in the gene encoding gp91phox (<em>CYBB</em>) are usually either missense (replacement of the correct amino acid with an incorrect one but preserving protein synthesis) or nonsense (replacement of an amino acid with a stop codon leading to protein truncation and usually abrogating protein synthesis). Nonsense variants generally lead to more severe CGD with diminished survival. Missense variants that are in amino acids 1 to 309 are associated with residual superoxide formation, slight DHR positivity, and better survival. In contrast, variants at amino acids 310 and beyond affect critical protein functional domains and usually lead to complete loss of DHR activity, more severe CGD, and diminished survival [<a href="#rid33">33</a>]. Thus, gene sequencing can be used without further functional studies to predict relative mortality risk and counsel regarding bone marrow transplantation or gene therapy.</p><p class="headingAnchor" id="H37"><span class="h2">Prenatal diagnosis</span><span class="headingEndMark"> — </span>If the precise pathogenic variant of a family member with CGD is known, then chorionic villus or amniotic fluid sampling can be performed to obtain a sample for genotyping of the fetus. Another testing option is to sample fetal blood and perform a DHR test.</p><p class="headingAnchor" id="H38"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of CGD mainly involves disorders associated with recurrent and/or unusually severe infections, particularly those caused by the pathogens commonly associated with the disease (see <a class="local">'Infections'</a> above). However, it is usually possible to differentiate between these diseases and CGD when the entire clinical picture is examined. The differential diagnosis may consider:</p><p class="bulletIndent1"><span class="glyph">●</span>Cystic fibrosis (CF)</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperimmunoglobulin E syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Glucose-6-phosphate dehydrogenase (G6PD) deficiency</p><p class="bulletIndent1"><span class="glyph">●</span>Glutathione synthetase (GS) deficiency</p><p class="bulletIndent1"><span class="glyph">●</span>Crohn disease (in patients with inflammation limited to the rectum)</p><p></p><p>Patients with CF may develop <em>B. cepacia</em> complex infections. However, the infections in patients with CF are limited to the lung and typically occur in the setting of significant bronchiectasis, which is not as common in patients with CGD. (See  <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">"Cystic fibrosis: Clinical manifestations and diagnosis"</a>.)</p><p>Patients with hyperimmunoglobulin E syndrome develop staphylococcal infections and may develop <em>Aspergillus</em> infections in the lung. However, the <em>Aspergillus</em> infections occur only in the setting of preexisting lung cysts, which are not common in patients with CGD. Also, hyperimmunoglobulin E patients have characteristic facies and markedly elevated immunoglobulin E (IgE) levels, whereas CGD patients do not. (See  <a class="medical medical_review" href="/z/d/html/3960.html" rel="external">"Autosomal dominant hyperimmunoglobulin E syndrome"</a>.)</p><p>G6PD deficiency and GS deficiency affect the neutrophil respiratory burst and increase susceptibility to bacterial infections [<a href="#rid128">128-131</a>]. G6PD deficiency is most often associated with some degree of hemolytic anemia, whereas CGD is not. Severe GS deficiency is also associated with hemolytic anemia, in addition to 5-oxoprolinuria, acidosis, and intellectual disability. These disorders are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/3954.html" rel="external">"Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency"</a>.)</p><p>A report of protein kinase C (PKC) delta deficiency suggested that it should be considered in the differential diagnosis in young patients with CGD-like clinical manifestations and abnormal dihydrorhodamine (DHR) assay results, even in the absence of clinical and biological manifestations of autoimmunity [<a href="#rid132">132</a>].</p><p>Patients with Crohn disease have inflammatory bowel symptoms similar to those in CGD colitis. However, Crohn disease is not associated with severe infections, as is CGD. While Crohn disease can involve any part of the gastrointestinal tract and may have extraintestinal manifestations, CGD colitis is more often rectal and perirectal and is not associated with extraintestinal manifestations. Histopathologically, CGD bowel biopsies have lipid-laden macrophages, which are not characteristic of Crohn disease.</p><p>In vitro, the respiratory burst may also be inhibited by diverse pathogens, including <em>Legionella pneumophila</em>, <em>Toxoplasma gondii</em>, <em>Chlamydia</em>, <em>Entamoeba histolytica</em>, and <em>Ehrlichia risticii</em>. Human granulocytic ehrlichiosis infection depresses the respiratory burst by downregulating gp91phox [<a href="#rid133">133</a>]. This effect is not diagnostically significant.</p><p class="headingAnchor" id="H3917800219"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H16404299"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83030.html" rel="external">"Patient education: Chronic granulomatous disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H39"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and age at diagnosis</strong> – Chronic granulomatous disease (CGD) is a genetically heterogeneous condition characterized by recurrent, life-threatening bacterial and fungal infections and granuloma formation. Most patients are diagnosed before the age of five years. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – CGD is caused by defects in phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which comprises the phagocyte oxidase (phox). This enzyme complex is responsible for the phagocyte respiratory burst. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic defects</strong> – Pathogenic variants in the genes for all six proteins (gp91phox, p47phox, p22phox, p67phox, p40phox, and essential for reactive oxygen species [EROS]) that make up the NADPH oxidase complex account for all of the known cases of CGD. Most pathogenic variants in North America are X linked (gp91phox deficiency). (See <a class="local">'Genetic defects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types and sites of infections</strong> – Patients with CGD typically experience recurrent infections caused by bacterial and fungal pathogens. The overwhelming majority of infections in patients with CGD living in North America are due to five organisms: <em>Staphylococcus aureus</em>, <em>Burkholderia cepacia</em> complex, <em>Serratia marcescens</em>, <em>Nocardia</em>, and <em>Aspergillus</em>. The frequent sites of infection are lung, skin, lymph nodes, and liver. (See <a class="local">'Infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory manifestations</strong> – Patients with CGD are prone to the formation of granulomata that are especially problematic in the gastrointestinal and genitourinary tracts. Colitis is a common gastrointestinal manifestation. (See <a class="local">'Inflammatory and other manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carriers</strong> – Female carriers generally do not have an increased rate of infections, but they are more predisposed to certain inflammatory manifestations associated with CGD. However, females can develop typical CGD infections when oxidase activity drops to &lt;20 percent of normal due to skewed X-chromosome lyonization. (See <a class="local">'X-linked carriers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A neutrophil function test, dihydrorhodamine (DHR) 123, is the initial diagnostic test performed. A significantly abnormal finding should be confirmed by genotyping. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H1603299978"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p><p>The UpToDate editorial staff also acknowledges Sergio D Rosenzweig, MD, who contributed as an author to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Marciano BE, Rosenzweig SD, Kleiner DE, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 2004; 114:462.</a></li><li><a class="nounderline abstract_t">Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79:155.</a></li><li><a class="nounderline abstract_t">Suliaman F, Amra N, Sheikh S, et al. Epidemiology of chronic granulomatous disease of childhood in Eastern Province, Saudi Arabia. Pediatr Asthma Allergy Immunol 2009; 22:21.</a></li><li><a class="nounderline abstract_t">Jones LB, McGrogan P, Flood TJ, et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol 2008; 152:211.</a></li><li><a class="nounderline abstract_t">Kobayashi S, Murayama S, Takanashi S, et al. Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatr 2008; 167:1389.</a></li><li><a class="nounderline abstract_t">Martire B, Rondelli R, Soresina A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin Immunol 2008; 126:155.</a></li><li><a class="nounderline abstract_t">Soler-Palacín P, Margareto C, Llobet P, et al. Chronic granulomatous disease in pediatric patients: 25 years of experience. Allergol Immunopathol (Madr) 2007; 35:83.</a></li><li><a class="nounderline abstract_t">van den Berg JM, van Koppen E, Ahlin A, et al. Chronic granulomatous disease: the European experience. PLoS One 2009; 4:e5234.</a></li><li><a class="nounderline abstract_t">Segal BH, Leto TL, Gallin JI, et al. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000; 79:170.</a></li><li><a class="nounderline abstract_t">Arnadottir GA, Norddahl GL, Gudmundsdottir S, et al. A homozygous loss-of-function mutation leading to CYBC1 deficiency causes chronic granulomatous disease. Nat Commun 2018; 9:4447.</a></li><li><a class="nounderline abstract_t">Segal AW. The electron transport chain of the microbicidal oxidase of phagocytic cells and its involvement in the molecular pathology of chronic granulomatous disease. J Clin Invest 1989; 1057:281.</a></li><li><a class="nounderline abstract_t">Dinauer MC. The respiratory burst oxidase and the molecular genetics of chronic granulomatous disease. Crit Rev Clin Lab Sci 1993; 30:329.</a></li><li><a class="nounderline abstract_t">Borregaard N. Neutrophils, from marrow to microbes. Immunity 2010; 33:657.</a></li><li><a class="nounderline abstract_t">Flannagan RS, Jaumouillé V, Grinstein S. The cell biology of phagocytosis. Annu Rev Pathol 2012; 7:61.</a></li><li><a class="nounderline abstract_t">Reeves EP, Lu H, Jacobs HL, et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 2002; 416:291.</a></li><li><a class="nounderline abstract_t">Bode K, Hauri-Hohl M, Jaquet V, Weyd H. Unlocking the power of NOX2: A comprehensive review on its role in immune regulation. Redox Biol 2023; 64:102795.</a></li><li><a class="nounderline abstract_t">Garay JA, Silva JE, Di Genaro MS, Davicino RC. The Multiple Faces of Nitric Oxide in Chronic Granulomatous Disease: A Comprehensive Update. Biomedicines 2022; 10.</a></li><li><a class="nounderline abstract_t">McCann KJ, Christensen SM, Colby DH, et al. IFNγ regulates NAD+ metabolism to promote the respiratory burst in human monocytes. Blood Adv 2022; 6:3821.</a></li><li><a class="nounderline abstract_t">Hartl D, Lehmann N, Hoffmann F, et al. Dysregulation of innate immune receptors on neutrophils in chronic granulomatous disease. J Allergy Clin Immunol 2008; 121:375.</a></li><li><a class="nounderline abstract_t">Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007; 5:577.</a></li><li><a class="nounderline abstract_t">Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303:1532.</a></li><li><a class="nounderline abstract_t">Bianchi M, Niemiec MJ, Siler U, et al. Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. J Allergy Clin Immunol 2011; 127:1243.</a></li><li><a class="nounderline abstract_t">Bianchi M, Hakkim A, Brinkmann V, et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 2009; 114:2619.</a></li><li><a class="nounderline abstract_t">Miyabe Y, Yano M, Fukuchi M, et al. Neutrophil and eosinophil ETosis-mediated extracellular trap formation in a patient with chronic granulomatous disease. Allergol Int 2023; 72:176.</a></li><li><a class="nounderline abstract_t">Brown KL, Bylund J, MacDonald KL, et al. ROS-deficient monocytes have aberrant gene expression that correlates with inflammatory disorders of chronic granulomatous disease. Clin Immunol 2008; 129:90.</a></li><li><a class="nounderline abstract_t">van de Veerdonk FL, Smeekens SP, Joosten LA, et al. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A 2010; 107:3030.</a></li><li><a class="nounderline abstract_t">Meissner F, Seger RA, Moshous D, et al. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 2010; 116:1570.</a></li><li><a class="nounderline abstract_t">van Bruggen R, Köker MY, Jansen M, et al. Human NLRP3 inflammasome activation is Nox1-4 independent. Blood 2010; 115:5398.</a></li><li><a class="nounderline abstract_t">Fernandez-Boyanapalli RF, Frasch SC, McPhillips K, et al. Impaired apoptotic cell clearance in CGD due to altered macrophage programming is reversed by phosphatidylserine-dependent production of IL-4. Blood 2009; 113:2047.</a></li><li><a class="nounderline abstract_t">Sanmun D, Witasp E, Jitkaew S, et al. Involvement of a functional NADPH oxidase in neutrophils and macrophages during programmed cell clearance: implications for chronic granulomatous disease. Am J Physiol Cell Physiol 2009; 297:C621.</a></li><li><a class="nounderline abstract_t">Fernandez-Boyanapalli RF, Falcone EL, Zerbe CS, et al. Impaired efferocytosis in human chronic granulomatous disease is reversed by pioglitazone treatment. J Allergy Clin Immunol 2015; 136:1399.</a></li><li><a class="nounderline abstract_t">Roos D, Kuhns DB, Maddalena A, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis 2010; 45:246.</a></li><li><a class="nounderline abstract_t">Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010; 363:2600.</a></li><li><a class="nounderline abstract_t">Dekker J, de Boer M, Roos D. Gene-scan method for the recognition of carriers and patients with p47(phox)-deficient autosomal recessive chronic granulomatous disease. Exp Hematol 2001; 29:1319.</a></li><li><a class="nounderline abstract_t">Roos D, Kuhns DB, Maddalena A, et al. Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). Blood Cells Mol Dis 2010; 44:291.</a></li><li><a class="nounderline abstract_t">Matute JD, Arias AA, Wright NA, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 2009; 114:3309.</a></li><li><a class="nounderline abstract_t">van de Geer A, Nieto-Patlán A, Kuhns DB, et al. Inherited p40phox deficiency differs from classic chronic granulomatous disease. J Clin Invest 2018; 128:3957.</a></li><li><a class="nounderline abstract_t">Randzavola LO, Mortimer PM, Garside E, et al. EROS is a selective chaperone regulating the phagocyte NADPH oxidase and purinergic signalling. Elife 2022; 11.</a></li><li><a class="nounderline abstract_t">Hsu AP. Not too little, not too much: the impact of mutation types in Wiskott-Aldrich syndrome and RAC2 patients. Clin Exp Immunol 2023; 212:137.</a></li><li><a class="nounderline abstract_t">Kurkchubasche AG, Panepinto JA, Tracy TF Jr, et al. Clinical features of a human Rac2 mutation: a complex neutrophil dysfunction disease. J Pediatr 2001; 139:141.</a></li><li><a class="nounderline abstract_t">Accetta D, Syverson G, Bonacci B, et al. Human phagocyte defect caused by a Rac2 mutation detected by means of neonatal screening for T-cell lymphopenia. J Allergy Clin Immunol 2011; 127:535.</a></li><li><a class="nounderline abstract_t">Hsu AP, Donkó A, Arrington ME, et al. Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects. Blood 2019; 133:1977.</a></li><li><a class="nounderline abstract_t">Bustamante J, Arias AA, Vogt G, et al. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol 2011; 12:213.</a></li><li><a class="nounderline abstract_t">Esfandbod M, Kabootari M. Images in clinical medicine. Chronic granulomatous disease. N Engl J Med 2012; 367:753.</a></li><li><a class="nounderline abstract_t">Marciano BE, Spalding C, Fitzgerald A, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis 2015; 60:1176.</a></li><li><a class="nounderline abstract_t">Dorman SE, Guide SV, Conville PS, et al. Nocardia infection in chronic granulomatous disease. Clin Infect Dis 2002; 35:390.</a></li><li><a class="nounderline abstract_t">Segal BH, DeCarlo ES, Kwon-Chung KJ, et al. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998; 77:345.</a></li><li><a class="nounderline abstract_t">Galluzzo ML, Hernandez C, Davila MT, et al. Clinical and histopathological features and a unique spectrum of organisms significantly associated with chronic granulomatous disease osteomyelitis during childhood. Clin Infect Dis 2008; 46:745.</a></li><li><a class="nounderline abstract_t">Bortoletto P, Lyman K, Camacho A, et al. Chronic Granulomatous Disease: A Large, Single-center US Experience. Pediatr Infect Dis J 2015; 34:1110.</a></li><li><a class="nounderline abstract_t">Salvator H, Mahlaoui N, Catherinot E, et al. Pulmonary manifestations in adult patients with chronic granulomatous disease. Eur Respir J 2015; 45:1613.</a></li><li><a class="nounderline abstract_t">Reichenbach J, Lopatin U, Mahlaoui N, et al. Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen. Clin Infect Dis 2009; 49:1703.</a></li><li><a class="nounderline abstract_t">Falcone EL, Petts JR, Fasano MB, et al. Methylotroph Infections and Chronic Granulomatous Disease. Emerg Infect Dis 2016; 22:404.</a></li><li><a class="nounderline abstract_t">Ramanuja S, Wolf KM, Sadat MA, et al. Newly diagnosed chronic granulomatous disease in a 53-year-old woman with Crohn disease. Ann Allergy Asthma Immunol 2005; 95:204.</a></li><li><a class="nounderline abstract_t">Greenberg DE, Goldberg JB, Stock F, et al. Recurrent Burkholderia infection in patients with chronic granulomatous disease: 11-year experience at a large referral center. Clin Infect Dis 2009; 48:1577.</a></li><li><a class="nounderline abstract_t">Valentine G, Thomas TA, Nguyen T, Lai YC. Chronic granulomatous disease presenting as hemophagocytic lymphohistiocytosis: a case report. Pediatrics 2014; 134:e1727.</a></li><li><a class="nounderline abstract_t">Álvarez-Cardona A, Rodríguez-Lozano AL, Blancas-Galicia L, et al. Intravenous immunoglobulin treatment for macrophage activation syndrome complicating chronic granulomatous disease. J Clin Immunol 2012; 32:207.</a></li><li><a class="nounderline abstract_t">Friend JC, Hilligoss DM, Marquesen M, et al. Skin ulcers and disseminated abscesses are characteristic of Serratia marcescens infection in older patients with chronic granulomatous disease. J Allergy Clin Immunol 2009; 124:164.</a></li><li><a class="nounderline abstract_t">Bustamante J, Aksu G, Vogt G, et al. BCG-osis and tuberculosis in a child with chronic granulomatous disease. J Allergy Clin Immunol 2007; 120:32.</a></li><li><a class="nounderline abstract_t">Lau YL, Chan GC, Ha SY, et al. The role of phagocytic respiratory burst in host defense against Mycobacterium tuberculosis. Clin Infect Dis 1998; 26:226.</a></li><li><a class="nounderline abstract_t">Lee PP, Chan KW, Jiang L, et al. Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr Infect Dis J 2008; 27:224.</a></li><li><a class="nounderline abstract_t">Ishikawa T, Okai M, Mochizuki E, et al. Bacillus Calmette-Guérin (BCG) Infections at High Frequency in Both AR-CGD and X-CGD Patients Following BCG Vaccination. Clin Infect Dis 2021; 73:e2538.</a></li><li><a class="nounderline abstract_t">Greenberg DE, Ding L, Zelazny AM, et al. A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog 2006; 2:e28.</a></li><li><a class="nounderline abstract_t">Greenberg DE, Shoffner AR, Zelazny AM, et al. Recurrent Granulibacter bethesdensis infections and chronic granulomatous disease. Emerg Infect Dis 2010; 16:1341.</a></li><li><a class="nounderline abstract_t">López FC, de Luna FF, Delgado MC, et al. Granulibacter bethesdensis isolated in a child patient with chronic granulomatous disease. J Infect 2008; 57:275.</a></li><li><a class="nounderline abstract_t">Rebelo M, Ding L, Cordeiro AI, et al. Fatal Meningitis in Patient with X-Linked Chronic Granulomatous Disease Caused by Virulent Granulibacter bethesdensis. Emerg Infect Dis 2019; 25:976.</a></li><li><a class="nounderline abstract_t">Sirinavin S, Techasaensiri C, Pakakasama S, et al. Hemophagocytic syndrome and Burkholderia cepacia splenic microabscesses in a child with chronic granulomatous disease. Pediatr Infect Dis J 2004; 23:882.</a></li><li><a class="nounderline abstract_t">Hisano M, Sugawara K, Tatsuzawa O, et al. Bacteria-associated haemophagocytic syndrome and septic pulmonary embolism caused by Burkholderia cepacia complex in a woman with chronic granulomatous disease. J Med Microbiol 2007; 56:702.</a></li><li><a class="nounderline abstract_t">Lacy DE, Spencer DA, Goldstein A, et al. Chronic granulomatous disease presenting in childhood with Pseudomonas cepacia septicaemia. J Infect 1993; 27:301.</a></li><li><a class="nounderline abstract_t">Macher AM, Casale TB, Fauci AS. Chronic granulomatous disease of childhood and Chromobacterium violaceum infections in the southeastern United States. Ann Intern Med 1982; 97:51.</a></li><li><a class="nounderline abstract_t">Mailman TL, Schmidt MH. Francisella philomiragia adenitis and pulmonary nodules in a child with chronic granulomatous disease. Can J Infect Dis Med Microbiol 2005; 16:245.</a></li><li><a class="nounderline abstract_t">Falcone EL, Holland SM. Streptococcal infections in patients with chronic granulomatous disease: case report and review of the literature. J Clin Immunol 2013; 33:310.</a></li><li><a class="nounderline abstract_t">Vinh DC, Shea YR, Sugui JA, et al. Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis 2009; 49:102.</a></li><li><a class="nounderline abstract_t">Vinh DC, Shea YR, Jones PA, et al. Chronic invasive aspergillosis caused by Aspergillus viridinutans. Emerg Infect Dis 2009; 15:1292.</a></li><li><a class="nounderline abstract_t">De Ravin SS, Challipalli M, Anderson V, et al. Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease. Clin Infect Dis 2011; 52:e136.</a></li><li><a class="nounderline abstract_t">Machouart M, Garcia-Hermoso D, Rivier A, et al. Emergence of disseminated infections due to Geosmithia argillacea in patients with chronic granulomatous disease receiving long-term azole antifungal prophylaxis. J Clin Microbiol 2011; 49:1681.</a></li><li><a class="nounderline abstract_t">Henriet SS, Verweij PE, Warris A. Aspergillus nidulans and chronic granulomatous disease: a unique host-pathogen interaction. J Infect Dis 2012; 206:1128.</a></li><li><a class="nounderline abstract_t">Santos PE, Piontelli E, Shea YR, et al. Penicillium piceum infection: diagnosis and successful treatment in chronic granulomatous disease. Med Mycol 2006; 44:749.</a></li><li><a class="nounderline abstract_t">Vinh DC, Freeman AF, Shea YR, et al. Mucormycosis in chronic granulomatous disease: association with iatrogenic immunosuppression. J Allergy Clin Immunol 2009; 123:1411.</a></li><li><a class="nounderline abstract_t">Lugo Reyes SO, Suarez F, Herbigneaux RM, et al. Hodgkin lymphoma in 2 children with chronic granulomatous disease. J Allergy Clin Immunol 2011; 127:543.</a></li><li><a class="nounderline abstract_t">Gilbert JA, Blaser MJ, Caporaso JG, et al. Current understanding of the human microbiome. Nat Med 2018; 24:392.</a></li><li><a class="nounderline abstract_t">Sharma M, Dhaliwal M, Tyagi R, et al. Microbiome and Its Dysbiosis in Inborn Errors of Immunity. Pathogens 2023; 12.</a></li><li><a class="nounderline abstract_t">Chandrasekaran P, Han Y, Zerbe CS, et al. Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease. J Allergy Clin Immunol 2023; 152:1619.</a></li><li><a class="nounderline abstract_t">Davrandi M, Harris S, Smith PJ, et al. The Relationship Between Mucosal Microbiota, Colitis, and Systemic Inflammation in Chronic Granulomatous Disorder. J Clin Immunol 2022; 42:312.</a></li><li><a class="nounderline abstract_t">Towbin AJ, Chaves I. Chronic granulomatous disease. Pediatr Radiol 2010; 40:657.</a></li><li><a class="nounderline abstract_t">Rosenzweig SD. Inflammatory manifestations in chronic granulomatous disease (CGD). J Clin Immunol 2008; 28 Suppl 1:S67.</a></li><li><a class="nounderline abstract_t">Khangura SK, Kamal N, Ho N, et al. Gastrointestinal Features of Chronic Granulomatous Disease Found During Endoscopy. Clin Gastroenterol Hepatol 2016; 14:395.</a></li><li><a class="nounderline abstract_t">Huang C, De Ravin SS, Paul AR, et al. Genetic Risk for Inflammatory Bowel Disease Is a Determinant of Crohn's Disease Development in Chronic Granulomatous Disease. Inflamm Bowel Dis 2016; 22:2794.</a></li><li><a class="nounderline abstract_t">Lowe DM, Smith PJ, Moreira F, et al. Chronic Granulomatous Disorder-Associated Colitis Can Be Accurately Evaluated with MRI Scans and Fecal Calprotectin Level. J Clin Immunol 2019; 39:494.</a></li><li><a class="nounderline abstract_t">Liu S, Russo PA, Baldassano RN, Sullivan KE. CD68 expression is markedly different in Crohn's disease and the colitis associated with chronic granulomatous disease. Inflamm Bowel Dis 2009; 15:1213.</a></li><li><a class="nounderline abstract_t">Pazmandi J, Kalinichenko A, Ardy RC, Boztug K. Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms. Immunol Rev 2019; 287:162.</a></li><li><a class="nounderline abstract_t">Uzel G, Orange JS, Poliak N, et al. Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010; 51:1429.</a></li><li><a class="nounderline abstract_t">Conrad A, Neven B, Mahlaoui N, et al. Infections in Patients with Chronic Granulomatous Disease Treated with Tumor Necrosis Factor Alpha Blockers for Inflammatory Complications. J Clin Immunol 2021; 41:185.</a></li><li><a class="nounderline abstract_t">Feld JJ, Hussain N, Wright EC, et al. Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology 2008; 134:1917.</a></li><li><a class="nounderline abstract_t">Straughan DM, McLoughlin KC, Mullinax JE, et al. The Changing Paradigm of Management of Liver Abscesses in Chronic Granulomatous Disease. Clin Infect Dis 2018; 66:1427.</a></li><li><a class="nounderline abstract_t">Walther MM, Malech H, Berman A, et al. The urological manifestations of chronic granulomatous disease. J Urol 1992; 147:1314.</a></li><li><a class="nounderline abstract_t">Siddiqui MR, Sanford T, Nair A, et al. Chronic Colovesical Fistula Leading to Chronic Urinary Tract Infection Resulting in End-Stage Renal Disease in a Chronic Granulomatous Disease Patient. Urol Case Rep 2017; 11:37.</a></li><li><a class="nounderline abstract_t">Goldblatt D, Butcher J, Thrasher AJ, Russell-Eggitt I. Chorioretinal lesions in patients and carriers of chronic granulomatous disease. J Pediatr 1999; 134:780.</a></li><li><a class="nounderline abstract_t">Wang Y, Marciano BE, Shen D, et al. Molecular identification of bacterial DNA in the chorioretinal scars of chronic granulomatous disease. J Clin Immunol 2013; 33:917.</a></li><li><a class="nounderline abstract_t">Siddiqui S, Anderson VL, Hilligoss DM, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis 2007; 45:673.</a></li><li><a class="nounderline abstract_t">Cohen MS, Leong PA, Simpson DM. Phagocytic cells in periodontal defense. Periodontal status of patients with chronic granulomatous disease of childhood. J Periodontol 1985; 56:611.</a></li><li><a class="nounderline abstract_t">Oveisi M, Barzilay O, Hanafi AA. Periodontal Disease in Immunodeficient Patients: Clinical Guidelines for Diagnosis and Management. International Dental Journal of Student’s Research 2015; 3:95.</a></li><li><a class="nounderline abstract_t">Manzi S, Urbach AH, McCune AB, et al. Systemic lupus erythematosus in a boy with chronic granulomatous disease: case report and review of the literature. Arthritis Rheum 1991; 34:101.</a></li><li><a class="nounderline abstract_t">Cale CM, Morton L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol 2007; 148:79.</a></li><li><a class="nounderline abstract_t">De Ravin SS, Naumann N, Cowen EW, et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol 2008; 122:1097.</a></li><li><a class="nounderline abstract_t">Buescher ES, Gallin JI. Stature and weight in chronic granulomatous disease. J Pediatr 1984; 104:911.</a></li><li><a class="nounderline abstract_t">Soncini E, Slatter MA, Jones LB, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 2009; 145:73.</a></li><li><a class="nounderline abstract_t">Marsh WL, Oyen R, Nichols ME, Allen FH Jr. Chronic granulomatous disease and the Kell blood groups. Br J Haematol 1975; 29:247.</a></li><li><a class="nounderline abstract_t">Frey D, Mächler M, Seger R, et al. Gene deletion in a patient with chronic granulomatous disease and McLeod syndrome: fine mapping of the Xk gene locus. Blood 1988; 71:252.</a></li><li><a class="nounderline abstract_t">Repine JE, Clawson CC, White JG, Holmes B. Spectrum of function of neutrophils from carriers of sex-linked chronic granulomatous disease. J Pediatr 1975; 87:901.</a></li><li><a class="nounderline abstract_t">Anderson-Cohen M, Holland SM, Kuhns DB, et al. Severe phenotype of chronic granulomatous disease presenting in a female with a de novo mutation in gp91-phox and a non familial, extremely skewed X chromosome inactivation. Clin Immunol 2003; 109:308.</a></li><li><a class="nounderline abstract_t">Wolach B, Scharf Y, Gavrieli R, et al. Unusual late presentation of X-linked chronic granulomatous disease in an adult female with a somatic mosaic for a novel mutation in CYBB. Blood 2005; 105:61.</a></li><li><a class="nounderline abstract_t">Roesler J. Carriers of X-linked chronic granulomatous disease at risk. Clin Immunol 2009; 130:233; author reply 234.</a></li><li><a class="nounderline abstract_t">Lewis EM, Singla M, Sergeant S, et al. X-linked chronic granulomatous disease secondary to skewed X chromosome inactivation in a female with a novel CYBB mutation and late presentation. Clin Immunol 2008; 129:372.</a></li><li><a class="nounderline abstract_t">Marciano BE, Zerbe CS, Falcone EL, et al. X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability. J Allergy Clin Immunol 2018; 141:365.</a></li><li><a class="nounderline abstract_t">Rösen-Wolff A, Soldan W, Heyne K, et al. Increased susceptibility of a carrier of X-linked chronic granulomatous disease (CGD) to Aspergillus fumigatus infection associated with age-related skewing of lyonization. Ann Hematol 2001; 80:113.</a></li><li><a class="nounderline abstract_t">Brandrup F, Koch C, Petri M, et al. Discoid lupus erythematosus-like lesions and stomatitis in female carriers of X-linked chronic granulomatous disease. Br J Dermatol 1981; 104:495.</a></li><li><a class="nounderline abstract_t">Kragballe K, Borregaard N, Brandrup F, et al. Relation of monocyte and neutrophil oxidative metabolism to skin and oral lesions in carriers of chronic granulomatous disease. Clin Exp Immunol 1981; 43:390.</a></li><li><a class="nounderline abstract_t">Chiriaco M, Salfa I, Ursu GM, et al. Immunological Aspects of X-Linked Chronic Granulomatous Disease Female Carriers. Antioxidants (Basel) 2021; 10.</a></li><li><a class="nounderline abstract_t">Bleesing JJ, Souto-Carneiro MM, Savage WJ, et al. Patients with chronic granulomatous disease have a reduced peripheral blood memory B cell compartment. J Immunol 2006; 176:7096.</a></li><li><a class="nounderline abstract_t">Heltzer M, Jawad AF, Rae J, et al. Diminished T cell numbers in patients with chronic granulomatous disease. Clin Immunol 2002; 105:273.</a></li><li><a class="nounderline abstract_t">Vowells SJ, Sekhsaria S, Malech HL, et al. Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J Immunol Methods 1995; 178:89.</a></li><li><a class="nounderline abstract_t">Vowells SJ, Fleisher TA, Sekhsaria S, et al. Genotype-dependent variability in flow cytometric evaluation of reduced nicotinamide adenine dinucleotide phosphate oxidase function in patients with chronic granulomatous disease. J Pediatr 1996; 128:104.</a></li><li><a class="nounderline abstract_t">Donko A, Kuhns DB, Cousin MA, et al. Interpretation of Dihydrorhodamine-1,2,3 Flow Cytometry in Chronic Granulomatous Disease: an Atypical Exemplar. J Clin Immunol 2022; 42:986.</a></li><li><a class="nounderline abstract_t">Mauch L, Lun A, O'Gorman MR, et al. Chronic granulomatous disease (CGD) and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD. Clin Chem 2007; 53:890.</a></li><li><a class="nounderline abstract_t">Ferguson PJ, Lokuta MA, El-Shanti HI, et al. Neutrophil dysfunction in a family with a SAPHO syndrome-like phenotype. Arthritis Rheum 2008; 58:3264.</a></li><li><a class="nounderline abstract_t">Kim HY, Kim HJ, Ki CS, et al. Rapid determination of chimerism status using dihydrorhodamine assay in a patient with X-linked chronic granulomatous disease following hematopoietic stem cell transplantation. Ann Lab Med 2013; 33:288.</a></li><li><a class="nounderline abstract_t">Almutairi A, Zaman F, Day-Lewis M, et al. Acetaminophen Inhibits the Neutrophil Oxidative Burst: Implications for Diagnostic Testing. J Allergy Clin Immunol Pract 2020; 8:3543.</a></li><li><a class="nounderline abstract_t">Roos D, van Zwieten R, Wijnen JT, et al. Molecular basis and enzymatic properties of glucose 6-phosphate dehydrogenase volendam, leading to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 1999; 94:2955.</a></li><li><a class="nounderline abstract_t">Whitin JC, Cohen HJ. Disorders of respiratory burst termination. Hematol Oncol Clin North Am 1988; 2:289.</a></li><li><a class="nounderline abstract_t">Ristoff E, Mayatepek E, Larsson A. Long-term clinical outcome in patients with glutathione synthetase deficiency. J Pediatr 2001; 139:79.</a></li><li><a class="nounderline abstract_t">Sun B, Li Q, Dong X, et al. Severe G6PD deficiency leads to recurrent infections and defects in ROS production: Case report and literature review. Front Genet 2022; 13:1035673.</a></li><li><a class="nounderline abstract_t">Neehus AL, Tuano K, Le Voyer T, et al. Chronic Granulomatous Disease-Like Presentation of a Child with Autosomal Recessive PKCδ Deficiency. J Clin Immunol 2022; 42:1244.</a></li><li><a class="nounderline abstract_t">Banerjee R, Anguita J, Roos D, Fikrig E. Cutting edge: infection by the agent of human granulocytic ehrlichiosis prevents the respiratory burst by down-regulating gp91phox. J Immunol 2000; 164:3946.</a></li></ol></div><div id="topicVersionRevision">Topic 3925 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15286231" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Gastrointestinal involvement in chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10844935" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Chronic granulomatous disease. Report on a national registry of 368 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology of chronic granulomatous disease of childhood in Eastern Province, Saudi Arabia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410635" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18335239" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18037347" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17594870" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chronic granulomatous disease in pediatric patients: 25 years of experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19381301" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chronic granulomatous disease: the European experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10844936" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Genetic, biochemical, and clinical features of chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30361506" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A homozygous loss-of-function mutation leading to CYBC1 deficiency causes chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The electron transport chain of the microbicidal oxidase of phagocytic cells and its involvement in the molecular pathology of chronic granulomatous disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8110374" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The respiratory burst oxidase and the molecular genetics of chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21094463" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Neutrophils, from marrow to microbes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21910624" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The cell biology of phagocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11907569" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Killing activity of neutrophils is mediated through activation of proteases by K+ flux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37379662" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Unlocking the power of NOX2: A comprehensive review on its role in immune regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36289832" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The Multiple Faces of Nitric Oxide in Chronic Granulomatous Disease: A Comprehensive Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35500221" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : IFNγregulates NAD+ metabolism to promote the respiratory burst in human monocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18155283" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Dysregulation of innate immune receptors on neutrophils in chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17632569" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Beneficial suicide: why neutrophils die to make NETs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15001782" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Neutrophil extracellular traps kill bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21376380" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19541821" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Restoration of NET formation by gene therapy in CGD controls aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36050253" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neutrophil and eosinophil ETosis-mediated extracellular trap formation in a patient with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676204" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : ROS-deficient monocytes have aberrant gene expression that correlates with inflammatory disorders of chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20133696" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20495074" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20407038" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Human NLRP3 inflammasome activation is Nox1-4 independent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18952895" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Impaired apoptotic cell clearance in CGD due to altered macrophage programming is reversed by phosphatidylserine-dependent production of IL-4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570889" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Involvement of a functional NADPH oxidase in neutrophils and macrophages during programmed cell clearance: implications for chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26386811" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Impaired efferocytosis in human chronic granulomatous disease is reversed by pioglitazone treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20729109" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hematologically important mutations: X-linked chronic granulomatous disease (third update).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21190454" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Residual NADPH oxidase and survival in chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11698128" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Gene-scan method for the recognition of carriers and patients with p47(phox)-deficient autosomal recessive chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167518" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19692703" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29969437" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Inherited p40phox deficiency differs from classic chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36421765" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : EROS is a selective chaperone regulating the phagocyte NADPH oxidase and purinergic signalling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36617178" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Not too little, not too much: the impact of mutation types in Wiskott-Aldrich syndrome and RAC2 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11445809" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical features of a human Rac2 mutation: a complex neutrophil dysfunction disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21167572" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Human phagocyte defect caused by a Rac2 mutation detected by means of neonatal screening for T-cell lymphopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30723080" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21278736" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22913685" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Images in clinical medicine. Chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25537876" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Common severe infections in chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145721" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Nocardia infection in chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9772923" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Aspergillus nidulans infection in chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18220479" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical and histopathological features and a unique spectrum of organisms significantly associated with chronic granulomatous disease osteomyelitis during childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26181896" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chronic Granulomatous Disease: A Large, Single-center US Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25614174" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pulmonary manifestations in adult patients with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19874205" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26886412" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Methylotroph Infections and Chronic Granulomatous Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16136772" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Newly diagnosed chronic granulomatous disease in a 53-year-old woman with Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19400745" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Recurrent Burkholderia infection in patients with chronic granulomatous disease: 11-year experience at a large referral center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422023" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Chronic granulomatous disease presenting as hemophagocytic lymphohistiocytosis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22119934" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intravenous immunoglobulin treatment for macrophage activation syndrome complicating chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19477489" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Skin ulcers and disseminated abscesses are characteristic of Serratia marcescens infection in older patients with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17544093" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : BCG-osis and tuberculosis in a child with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9455564" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The role of phagocytic respiratory burst in host defense against Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18277931" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32712647" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Bacillus Calmette-Guérin (BCG) Infections at High Frequency in Both AR-CGD and X-CGD Patients Following BCG Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16617373" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20735916" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Recurrent Granulibacter bethesdensis infections and chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18558432" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Granulibacter bethesdensis isolated in a child patient with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31002074" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Fatal Meningitis in Patient with X-Linked Chronic Granulomatous Disease Caused by Virulent Granulibacter bethesdensis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15361735" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hemophagocytic syndrome and Burkholderia cepacia splenic microabscesses in a child with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446299" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Bacteria-associated haemophagocytic syndrome and septic pulmonary embolism caused by Burkholderia cepacia complex in a woman with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7508484" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Chronic granulomatous disease presenting in childhood with Pseudomonas cepacia septicaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7092006" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Chronic granulomatous disease of childhood and Chromobacterium violaceum infections in the southeastern United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18159552" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Francisella philomiragia adenitis and pulmonary nodules in a child with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23108438" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Streptococcal infections in patients with chronic granulomatous disease: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19489714" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Invasive aspergillosis due to Neosartorya udagawae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19751595" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Chronic invasive aspergillosis caused by Aspergillus viridinutans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21367720" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21270214" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Emergence of disseminated infections due to Geosmithia argillacea in patients with chronic granulomatous disease receiving long-term azole antifungal prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22829648" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Aspergillus nidulans and chronic granulomatous disease: a unique host-pathogen interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17127632" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Penicillium piceum infection: diagnosis and successful treatment in chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19368967" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Mucormycosis in chronic granulomatous disease: association with iatrogenic immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21168906" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Hodgkin lymphoma in 2 children with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29634682" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Current understanding of the human microbiome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37111404" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Microbiome and Its Dysbiosis in Inborn Errors of Immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37659505" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34731398" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The Relationship Between Mucosal Microbiota, Colitis, and Systemic Inflammation in Chronic Granulomatous Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20135113" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18193341" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Inflammatory manifestations in chronic granulomatous disease (CGD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545803" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Gastrointestinal Features of Chronic Granulomatous Disease Found During Endoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27861181" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Genetic Risk for Inflammatory Bowel Disease Is a Determinant of Crohn's Disease Development in Chronic Granulomatous Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31172380" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Chronic Granulomatous Disorder-Associated Colitis Can Be Accurately Evaluated with MRI Scans and Fecal Calprotectin Level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19229980" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : CD68 expression is markedly different in Crohn's disease and the colitis associated with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30565237" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21058909" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Complications of tumor necrosis factor-αblockade in chronic granulomatous disease-related colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33150502" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Infections in Patients with Chronic Granulomatous Disease Treated with Tumor Necrosis Factor Alpha Blockers for Inflammatory Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18439425" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29145578" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The Changing Paradigm of Management of Liver Abscesses in Chronic Granulomatous Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1569675" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The urological manifestations of chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28083485" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Chronic Colovesical Fistula Leading to Chronic Urinary Tract Infection Resulting in End-Stage Renal Disease in a Chronic Granulomatous Disease Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10356152" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Chorioretinal lesions in patients and carriers of chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23636897" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Molecular identification of bacterial DNA in the chorioretinal scars of chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17712749" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3863911" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Phagocytic cells in periodontal defense. Periodontal status of patients with chronic granulomatous disease of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Periodontal Disease in Immunodeficient Patients: Clinical Guidelines for Diagnosis and Management</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984766" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Systemic lupus erythematosus in a boy with chronic granulomatous disease: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17286762" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823651" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Chronic granulomatous disease as a risk factor for autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6726526" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Stature and weight in chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19222467" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1191546" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Chronic granulomatous disease and the Kell blood groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3334897" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Gene deletion in a patient with chronic granulomatous disease and McLeod syndrome: fine mapping of the Xk gene locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1185391" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Spectrum of function of neutrophils from carriers of sex-linked chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14697745" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Severe phenotype of chronic granulomatous disease presenting in a female with a de novo mutation in gp91-phox and a non familial, extremely skewed X chromosome inactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15308575" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Unusual late presentation of X-linked chronic granulomatous disease in an adult female with a somatic mosaic for a novel mutation in CYBB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19004669" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Carriers of X-linked chronic granulomatous disease at risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18774749" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : X-linked chronic granulomatous disease secondary to skewed X chromosome inactivation in a female with a novel CYBB mutation and late presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28528201" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11261321" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Increased susceptibility of a carrier of X-linked chronic granulomatous disease (CGD) to Aspergillus fumigatus infection associated with age-related skewing of lyonization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7236510" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Discoid lupus erythematosus-like lesions and stomatitis in female carriers of X-linked chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7273485" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Relation of monocyte and neutrophil oxidative metabolism to skin and oral lesions in carriers of chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34206017" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Immunological Aspects of X-Linked Chronic Granulomatous Disease Female Carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16709872" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Patients with chronic granulomatous disease have a reduced peripheral blood memory B cell compartment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12498808" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Diminished T cell numbers in patients with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7829869" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8551399" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Genotype-dependent variability in flow cytometric evaluation of reduced nicotinamide adenine dinucleotide phosphate oxidase function in patients with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35344128" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Interpretation of Dihydrorhodamine-1,2,3 Flow Cytometry in Chronic Granulomatous Disease: an Atypical Exemplar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17384005" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Chronic granulomatous disease (CGD) and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18821685" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Neutrophil dysfunction in a family with a SAPHO syndrome-like phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23826567" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Rapid determination of chimerism status using dihydrorhodamine assay in a patient with X-linked chronic granulomatous disease following hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32707237" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Acetaminophen Inhibits the Neutrophil Oxidative Burst: Implications for Diagnostic Testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10556177" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Molecular basis and enzymatic properties of glucose 6-phosphate dehydrogenase volendam, leading to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2839461" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Disorders of respiratory burst termination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11445798" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Long-term clinical outcome in patients with glutathione synthetase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36353116" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Severe G6PD deficiency leads to recurrent infections and defects in ROS production: Case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35585372" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Chronic Granulomatous Disease-Like Presentation of a Child with Autosomal Recessive PKCδDeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10754283" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Cutting edge: infection by the agent of human granulocytic ehrlichiosis prevents the respiratory burst by down-regulating gp91phox.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
